Table I.
Human amyloid fibrils whose atomic structures have been determined by cryo-electron microscopy (cryoEM) or solid-state nuclear magnetic resonance (ssNMR).
| Protein / peptide | Pathology / Function | Method | PDB ID | Year |
|---|---|---|---|---|
| Neurodegenerative Disease | ||||
| Amyloid-β | Alzheimer’s | ssNMR | 2LMN, 2LMO, 2LMP, 2LMQ | 2008 |
| Amyloid-β | Alzheimer’s | ssNMR | 2M4J | 2013 |
| Amyloid-β | Alzheimer’s | ssNMR | 2MPZ | 2015 |
| Amyloid-β | Alzheimer’s | cryoEM | 5OQV | 2017 |
| Amyloid-β | Alzheimer’s | cryoEM | 6SHS | 2019 |
| Amyloid-β | Alzheimer’s | ssNMR | 6TI5, 6TI6 | 2020 |
| α-synuclein | Parkinson’s | ssNMR | 2N0A | 2016 |
| α-synuclein | Parkinson’s | cryoEM | 6CU7*, 6CU8* | 2018 |
| α-synuclein | Parkinson’s | cryoEM | 6FLT*, 6H6B* | 2018 |
| α-synuclein | Parkinson’s | cryoEM | 6RT0*, 6SSX*, 6RTB*, 6SST* | 2019 |
| Tau | Alzheimer’s | cryoEM | 5O3L*, 5O3T* | 2017 |
| Tau | Alzheimer’s | cryoEM | 6HRE*, 6HRF* | 2018 |
| Tau | Pick’s | cryoEM | 6GX5* | 2018 |
| Tau | CTEa | cryoEM | 6NWP*, 6NWQ* | 2019 |
| Tau | CBDb | cryoEM | 6TJX* [6] | 2020 |
| Other Amyloid Diseases | ||||
| Amylin | T2 diabetes | cryoEM | 6VW2 | 2020 |
| Amylin | T2 diabetes | cryoEM | 6Y1A | 2020 |
| β2 microglobulin | Dialysis-related | cryoEM | 6GK3 | 2018 |
| Igc light chain | AALd | cryoEM | 6HUD* | 2018 |
| Ig light chain | AALd | cryoEM | 6IC3 | 2019 |
| Serum amyloid A | AAe | cryoEM | 6MST | 2018 |
| Prion | TSEf | cryoEM | 6LNI | 2020 |
| Transthyretin V30M | ATTRg | cryoEM | 6SDZ* | 2019 |
| Functional Amyloids | ||||
| β-endorphin | Storage | cryoEM | 6TUB [5] | 2020 |
| Glucagon | Storage | cryoEM | 6NZN | 2019 |
| RIPK1/RIPK3 | Signaling | ssNMR | 5V7Z | 2018 |
a
CTE – chronic traumatic encephalopathy
b
CBD – corticobasal degeneration
c
Ig – immunoglobulin
d
AAL – antibody light chain
e
AA – amyloid-A
f
TSE – transmissible spongiform encephalopathy
g
ATTR – amyloid transthyretin
*
Amyloid structures containing additional features that probably represent a bound cofactor